← TrialMatch
HomeTrials

Peripersonal Space Representation in Upper Limb Segmental Exclusion

This study aims to evaluate the representation of action peripersonal space (PPS) in subjects suffering from unilateral segmental exclusion syndrome of the upper limb compared to healthy control subjects. Segmental exclusion is defined by non-use or under-use of a limb segment without central nervous system damage. The

Condition(s)Segmental Exclusion Syndrome, Complex Regional Pain Syndrome (CRPS), Upper Limb Neglect (Peripheral)
StatusRecruiting
Study typeObservational
SummaryThis study aims to evaluate the representation of action peripersonal space (PPS) in subjects suffering from unilateral segmental exclusion syndrome of the upper limb compared to healthy control subjects. Segmental exclusion is defined by non-use or under-use of a limb segment without central nervous system damage. The study hypothesizes that this syndrome leads to a modification (shrinkage) of the PPS representation. Participants will perform reachability judgments in a Virtual Reality (VR) environment.
Who can participateInclusion Criteria (patients): * Age ≥ 18 years. * Presenting unilateral exclusion symptom of the upper limb or part of the hand evolving for \> 3 months. * No contraindication to force work in daily activities. * For patients with finger exclusion: at least 2 perturbed items related to exclusion on tests 3 and 4 of the "Bilan 400 points". * Affiliated to a social security scheme. * Able to understand simple orders. Inclusion Criteria (Controls): * Age ≥ 18 years. * No history of upper limb impairment with sequelae. Exclusion Criteria (All): * Visual impairments. * Central neurological pathology. * Unstabilized psychiatric pathology. * Communication or comprehension difficulties. * Under legal protection or unable to consent. * Pregnant or breastfeeding women. * Cervical pathology contrain
Ages18 Years
SexAll
Accepts healthy volunteersYes
Lead sponsorUnion de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est
LocationsNancy, France
Start date2025-12-04
NCT IDNCT07349173
Official listinghttps://clinicaltrials.gov/study/NCT07349173

🔍 Search all trials →